1.
Manag Care
; 27(2): 33-40, 2018 02.
Article
in English
| MEDLINE
| ID: mdl-29451468
ABSTRACT
As expected, pharmacy costs increased with the introduction of this new treatment in a market dominated by over-the-counter and generic treatments. On the other hand, outpatient GI-related and irritable bowel disease health care resource use and costs substantially decreased among commercial and Medicare patients following linaclotide treatment initiation.
Subject(s)
Guanylyl Cyclase C Agonists/economics , Health Care Costs , Insurance Coverage , Insurance, Health , Peptides/economics , Adult , Aged , Female , Guanylyl Cyclase C Agonists/administration & dosage , Health Care Costs/statistics & numerical data , Humans , Irritable Bowel Syndrome/drug therapy , Male , Middle Aged , Peptides/administration & dosage , Retrospective Studies , United States
2.
Manag Care
; 26(3): 36-37, 2017 03.
Article
in English
| MEDLINE
| ID: mdl-28510525
ABSTRACT
Constipation can be a serious and painful problem, and we shouldn't dismiss other people's suffering. On the other hand there's a danger when new medications are compared against placebo rather than against over-the-counter products with a history of effectiveness.
